A utoimmune endocrinopathies demonstrate a profound gender bias. In common with most autoimmune conditions, autoimmune Addison's disease (AAD) and Graves' disease (GD) exhibit a clear female preponderance. These complex diseases have an intricate, and as yet not fully explained, pattern of genetic susceptibility. The basis for female proclivity to autoimmunity is not well understood, but one hypothesis is that genetic variants on the X chromosome play an important role in the development of autoimmune disease.
The X chromosome contains approximately 1000 genes and is less well studied than might be expected, predominantly because of the lower power and higher complexity of analyses in genomic linkage and association studies. Recent reexamination of X chromosome data from a genome-wide association analysis of Chinese GD patients has identifiedasingle-nucleotidepolymorphism(SNP),rs3827440, in the Xq21 immune receptor GPR174, which may contribute to the unequal sex distribution of GD (1). This association with the GPR174 alleles was replicated in a Polish population of GD patients, suggesting a significant role in autoimmune thyroid disease in varied populations (2) .
GPR174 is a cell-surface receptor for lysophosphatidylserine and is highly expressed in the thymus, the spleen, and leukocytes (1) . Lysophosphatidylserine has a potential role as a lipid mediator, and although little is known about its precise role in vivo, it is believed to have endogenous antiinflammatory properties (3). The potential relevance of its function has prompted further examination of the role of GPR174 in autoimmune disease. AAD is a rare autoimmune disease, with a prevalence of 93-140 per million and an annual incidence of 4.7-6.2 per million (4) . It can present at any age but is most frequently diagnosed in women between 30 and 50 years of age, with a female to male ratio of 2-3:1 (5) . Approximately 50% of AAD patients have accompanying autoimmune thyroid diseases, including GD. A complex interplay of genetic, immunological, and environmental factors predispose to the development of symptomatic adrenocortical insufficiency (5). Patients require life-long corticosteroid replacement therapy, which is absolutely essential for survival (6) .
Several autoimmune conditions share genetic susceptibility factors, and consequently, the identification of GPR174 as immunologically relevant has the potential to impact not only our understanding of GD but also other autoimmune disease too. GD has a striking female preponderance, with a female to male ratio of 5-10:1 (7); although gains in knowledge surrounding X chromosome genes in this disease could enhance our understanding, there must be additional factors contributing to the disparity between the sexes in autoimmune endocrinopathies. In this study, we have explored the potential role of GPR174 in our UK cohort of patients with AAD.
Patients and Methods

Patients
In each subject with AAD, the clinical diagnosis was confirmed by either a low basal cortisol result with a high ACTH level or a subnormal response to the short synacthen test (250 g parenteral synthetic ACTH ). Only those patients with a clear autoimmune etiology, distinguished by a positive 21-hydroxylase antibody status, antiadrenal cell antibodies, or with concurrent autoimmune disease, were included. Subjects with primary adrenal failure due to adrenal gland infiltration or infection, those with secondary adrenal failure, or those with autoimmune polyendocrine syndrome type 1 (on the grounds of mucocutaneous candidiasis, hypoparathyroidism, and/or ectodermal dystrophy) were excluded. One hundred forty-nine of the 286 patients (52%) had additional coexisting autoimmune disease including thyroid dysfunction, type 1 diabetes, and pernicious anemia. Most of these autoimmune polyendocrine syndrome type 2 (APS2) patients had a diagnosis of autoimmune hypothyroidism. In addition, 26% of patients had GD, and a smaller proportion had premature ovarian failure (12%), pernicious anemia (6%), and type 1 diabetes (3%).
SNP genotyping
DNA samples from 286 AAD patients and 288 control patients were genotyped for rs3827440 using TaqMan SNP genotyping assays (C_25954273_10) and real-time PCR (Applied Biosystems Inc 7900 and 7500) for allelic discrimination.
Quality control was ensured by the replication of 20% of the samples on each plate analyzed, and the inclusion of no template controls (negative controls) in each experiment run. A subset of experiments was duplicated on the ABI 7900 and 7500 platforms to ensure replicate results.
The sex of all patients with AAD and GD is recorded in a preexisting registry of DNA samples, and each patient had given prior consent for their DNA to be used for the purposes of research. The sex of the anonymous control samples was confirmed using an allele-based PCR discrimination assay for a size polymorphism in the amelogenin gene (AMELX/Y). No heterozygous male patients were identified.
Statistical analysis
Association was modeled using either a present or absent allelic (dominant) model or using an allele dosage model, weighting females as 0, 1, or 2 and males as 0 or 2. Logistic regression using sex as an independent variable was performed using the survival package in R (8) .
Results
With the use of a dominant (present/absent) model in both male and female cases, the serine-encoding T allele of (Table 1) . When analyzed using an allele dosage model (a heterozygous female being weighted midway between homozygotes), a significant excess of the T allele was present in AAD patients compared with controls [P ϭ .03, OR 1.34 (5%-95% CI 1.07-1.67)].
A more striking disparity in T allele frequency between AAD patients and controls is demonstrated in male patients (Table 1) . Therefore, although our findings cannot explain female proclivity to AAD, they do emphasize the relevance of X chromosome genes in the development of this, and other, autoimmune endocrinopathies.
The subgroup of patients with APS2 did not exhibit a greater excess of the T allele than those with isolated AAD (P ϭ .55) ( Table 2 ), signifying that the identified positive association is attributable to AAD, rather than a separate, concurrent autoimmune disease.
Discussion
The rationale for gender bias in autoimmune endocrine diseases remains obscure, and both genetic and hormonal factors have been proposed. Initial genetic linkage analyses revealed an Xq11 locus that appeared to contribute toward Graves' disease susceptibility (9) . The identification of forkhead box P3, located on Xp11, as a master determinant of regulatory T cells (10) , also ignited interest in the suggestion that X chromosome loci could contribute to the gender bias in autoimmune disease. Nevertheless, SNPs in forkhead box P3 were not associated with disease in a large cohort of GD patients or in AAD (11) . Additional hypotheses, including skewed X chromosome inactivation (12, 13) and fetal microchimerism (14, 15) are often considered to be imperative. However, no single mechanism has been widely accepted as the dominant factor in female gender bias to autoimmunity.
Our study shows significant association of a serine to proline nonsynonymous variant (rs3827440, encoding S162P) in the X chromosome-encoded immunoreceptor GPR174 with AAD. This variant was previously shown to contribute toward GD susceptibility; we demonstrate for the first time that it also contributes to nonthyroid autoimmune diseases including AAD. Despite the greater female preponderance in GD, both AAD and GD (1, 2) show similar levels of association with this variant.
It is impossible to entirely separate the impact of genetic susceptibility to individual autoimmune conditions when the affected individual has more than one coexisting disease. Nevertheless, our subset analysis of those patients with APS2, vs those with isolated AAD, expands our knowledge of the role of this gene, specifically in AAD.
In addition to the expression in the thymus, the spleen, and leukocytes (1), GPR174 is expressed in thyroid and adrenal tissue (1, 16) . The GPR174 gene consists of one exon encoding a protein of 333 amino acids and is considered to be important in signal transduction in immune cells (1) . Importantly, the associated T allele of rs3827440 was found to be associated with greater GPR174 mRNA levels in human peripheral blood cells (1), suggesting a cis-acting effect of this variant, or a variant in linkage disequilibrium with it, on expression. Lysophosphatidylserine is known to inhibit mitogen-stimulated T lymphocyte activation (17) , and thus, GPR174 could mediate an important regulatory pathway connected to central T cell development and peripheral function.
Our finding of a novel GPR174 variant associated with AAD extends its potential relevance as a contributor to autoimmune endocrinopathies. Other diseases that possess an autoimmune component, including rheumatoid arthritis and systemic lupus erythematosus, should also be studied.
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